Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have received a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $61.33.

A number of equities research analysts recently issued reports on ARCT shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Finally, Citigroup raised their price target on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock opened at $26.32 on Friday. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $43.81. The company has a market capitalization of $708.53 million, a PE ratio of -25.31 and a beta of 2.60. The business’s fifty day moving average is $35.42 and its 200 day moving average is $29.75.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. On average, sell-side analysts forecast that Arcturus Therapeutics will post -1.42 EPS for the current fiscal year.

Insider Activity

In other news, COO Pad Chivukula sold 17,435 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the transaction, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at $16,580,148.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.80% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

Several large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Arcturus Therapeutics by 2.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,082 shares of the biotechnology company’s stock worth $508,000 after purchasing an additional 360 shares during the last quarter. SummerHaven Investment Management LLC grew its stake in shares of Arcturus Therapeutics by 1.7% in the fourth quarter. SummerHaven Investment Management LLC now owns 22,704 shares of the biotechnology company’s stock worth $716,000 after purchasing an additional 378 shares during the last quarter. Formidable Asset Management LLC grew its stake in shares of Arcturus Therapeutics by 3.3% in the fourth quarter. Formidable Asset Management LLC now owns 15,550 shares of the biotechnology company’s stock worth $490,000 after purchasing an additional 500 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Arcturus Therapeutics by 5.9% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 606 shares during the last quarter. Finally, Great West Life Assurance Co. Can grew its stake in shares of Arcturus Therapeutics by 29.9% in the first quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 616 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.